Glycogen Synthase Kinase 3 Inhibition Lowers PD-1 Expression, Promotes Long-term Survival and Memory Generation in Antigen-specific CAR-T cells

Successful remission in hematological cancers by CAR-T cell immunotherapy has yet to be replicated in solid tumors like GBM. A significant impediment of CAR-T immunotherapy in solid tumors is poor exposure of T cells to tumor antigens resulting in suboptimal CAR-T cell activation, which ultimately fails to induce a robust anti-tumor immune response. Costimulatory moieties in advanced-generation CARs, along with additional IL2 therapy has been shown to be insufficient to overcome this hurdle and have its cytotoxic limitations.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research